Shanghai Haohai Biological Technology Co., Ltd. provided preliminary unaudited consolidated earnings guidance for the three months ending March 31, 2021, For the period, the group expects that the net profit will turn around as compared to the corresponding period in 2020. The group is expected to record an unaudited net profit attributable to shareholders of the listed company of approximately RMB 80,000,000 to RMB 100,000,000 (corresponding period in 2020: an unaudited net loss attributable to shareholders of the listed company of RMB 24,855,428.82). The unaudited net profit attributable to shareholders of the listed company after deducting the non-recurring profit or loss is expected to be approximately RMB 75,000,000 to RMB 95,000,000 (corresponding period in 2020: unaudited net loss attributable to shareholders of the listed company after deducting the non-recurring profit or loss of RMB 35,711,082.59).